Nanoscope Therapeutics Announces New Clinical Advisory Board Appointments

April 19, 2021

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for the treatment of inherited retinal diseases, today announced an expansion of its Clinical Advisory Board with the appointment of four new members.

“We are honored to have such distinguished clinical experts in retinal disorders join us as advisers. Their guidance will be invaluable as we pioneer gene therapies to reprogram retinal cells and make them functionally active to regain vision,” said Nanoscope President and Co-Founder Samarendra Mohanty, Ph.D.

The four new members include:

  • Michael Singer, M.D., Clinical Professor of Ophthalmology at the University of Texas Health Science Center in San Antonio, Texas. He is also the Director of Clinical Research at Medical Center Ophthalmology Associates in San Antonio.
  • Stephen H. Tsang, M.D, Ph.D., the Laszlo T. Bito Professor of Ophthalmology, and Pathology and Cell Biology at Columbia University Irving Medical Center.
  • Paul Yang, M.D., Ph.D., Assistant Professor in Ophthalmic Genetics and Immunology at the Oregon Health & Science University Casey Eye Institute.
  • SriniVas R. Sadda, M.D., President and Chief Scientific Officer of the Doheny Eye Institute, the Stephen J. Ryan – Arnold and Mabel Beckman Endowed Chair, and Professor of Ophthalmology at the University of California – Los Angeles David Geffen School of Medicine.

The new members have joined current advisory board members: Samuel Barone, M.D.; Vittorio Porciatti, DSc; Weldon Wright, M.D.; and Thomas Yorio, Ph.D.

Nanoscope’s lead product is an optogenetic gene therapy, vMCO-010, that delivers light-sensitive Multi-Characteristics Opsin (MCO) into retinal cells to restore vision in patients with retinitis pigmentosa (RP) and Stargardt disease. Both applications have received orphan drug designation from the FDA. If successful, the optogenetic therapy would be the first treatment aimed at correcting these conditions.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution